Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Clinical Trials Related to Infigratinib
Related studies linked through entity extraction aliases.
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Status
- WITHDRAWN
- Phase
- PHASE1
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Status
- UNKNOWN
- Phase
- PHASE2
Phase I BLASST-3 Trial
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Infigratinib in Recurrent High-Grade Glioma Patients
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Status
- TERMINATED
- Phase
- PHASE3